Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer
2024-05-13
并购临床3期临床结果
Plus, news about OnKure:
Deciphera’s other bidder:
Before its acquisition by Ono Pharmaceutical, Deciphera had one other bidder that offered $19.00 per share, according to a new
SEC filing
. In total, Deciphera reached out to 23 companies to gauge buyout interest. Ultimately, Deciphera was
acquired
by Ono for $25.60 per share in April.
— Max Gelman
Bristol Myers Squibb reports lung cancer failure:
The
Phase 3 trial
was testing Opdivo plus chemo, followed by either Opdivo and Yervoy or Opdivo alone, against chemo followed by AstraZeneca’s Imfinzi in previously untreated patients with stage 3 non-small cell lung cancer whose tumors can’t be surgically removed. The primary endpoint, which was not achieved, was progression-free survival.
— Max Gelman
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。